PH is defined as the pressure level measured in the right heart catheterization of the patient at 25 mmHg and above (Küçükoğlu and Başkurt, 2010). According to the European Heart and respiratory associations definition of 2015, Pulmonary Hypertension (PH) is a physiopathological disorder involving multiple clinical conditions, making heart and respiratory system diseases more complex.
Today, PH is developing and watching with disease close to forty (Küçükoğlu and Selim, 2016). Although studies on PH have increased in recent years, it is a disease that causes high mortality and morbidity, decreases the life activities and quality of people, and concerns more than one branch (Küçükoğlu and Başkurt, 2010).
Symptoms and clinical table
Since PH is associated with many diseases, it is difficult to express the clinical ayo r that can be described as differential diagnosis today. In contrast, it is possible to summarize the general clinical table and the distribution by species as in Table 1.
PH is a heterogeneous disease that can ayo as a result of different diseases and clinical table (Küçükoğlu and Başkurt, 2010). ayo r s reason, not only the disease-specific clinical statements, but also the clinical features associated with the accompanying disease should be evaluated together.
In addition to genetic predisposition and heart disease, environmental factors also play an important role among PH risk factors. There are many studies, especially on Substance Use and drug interactions. It is possible to summarize the risk factors that ayo r may not be the cause of PH, as shown in Table 2.
Research has shown that congenital heart diseases are particularly important risk factors in the development of PH (Olgutturk, 2010). Therefore, the disease history, family history and birth history are also important in terms of research into risk factors.
In PH treatment, the diagnosis process must be successful first. Accordingly, the number of agents used in treatment is increasing. It is also useful to identify risk factors within the scope of Preventive Medicine and to continue the diagnostic process after the beginning of the medicated treatment process (Küçükoğlu and Selim, 2016).
ESC Guide, (2009). “Guidelines for the diagnosis and treatment of pulmonary hypertension”. Created by the European Cardiology Association (ESC) and the European Respiratory Society (ERS) Pulmonary Hypertension Diagnosis and Treatment Task Group, and the International Heart and Lung Transplantation Association (ISHLT), European Heart Journal,) 30 (1 ), 2493–2537.
Küçükoğlu MS and Başkurt M. (2010). "Pulmonary hypertension: diagnosis and clinical classification". Anadolu Kardiyol Derg, 10 (Suppl 1), 2-4.
Küçükoğlu MS and Selim ÜY. (2016). “New insights in the 2015 ESC Pulmonary Hypertension Guide”. Turk Kardiyol Dern Ars, 44 (1), 4-8.
Olguntürk, R. (2010). “Pediatric pulmonary hypertension and pulmonary arterial hypertension due to congenital heart diseases”.